Regeneron Pharmaceuticals Inc. buy Oppenheimer Holdings Inc.
Summary
This prediction ended on 07.11.25 with a price of €563.80. The prediction for Regeneron Pharmaceuticals Inc. disappointed with a performance of -26.66%. Oppenheimer_Holdings has a follow-up prediction for Regeneron Pharmaceuticals Inc. where he still thinks Regeneron Pharmaceuticals Inc. is a Buy. Dividends of €2.60 are taken into consideration when calculating the performance. Oppenheimer_Holdings has 50% into this predictionRegeneron Pharmaceuticals, Inc. is a biotechnology company that is engaged in the discovery, development, and commercialization of medicines for the treatment of serious medical conditions. The company's products include EYLEA, a treatment for wet age-related macular degeneration and diabetic macular edema; Dupixent, a treatment for atopic dermatitis and asthma; and Libtayo, a treatment for certain types of cancer. Regeneron also has a strong focus on research and development, with a pipeline of potential new treatments for a variety of diseases. The company is headquartered in Tarrytown, New York and trades on the NASDAQ stock exchange under the symbol REGN.
Performance without dividends (%)
| Name | 1w | 1m | 1y |
|---|---|---|---|
| Regeneron Pharmaceuticals Inc. | 0.113% | 0.113% | 19.855% |
| iShares Core DAX® | 1.352% | 2.740% | 7.868% |
| iShares Nasdaq 100 | 3.277% | 6.507% | 41.460% |
| iShares Nikkei 225® | 7.434% | 17.832% | 69.101% |
| iShares S&P 500 | 1.702% | 3.099% | 27.307% |
Comments by Oppenheimer_Holdings for this prediction
In the thread Regeneron Pharmaceuticals Inc. diskutieren
In the thread Trading Regeneron Pharmaceuticals Inc.
Current prediction by Oppenheimer_Holdings for Regeneron Pharmaceuticals Inc.
Regeneron Pharmaceuticals Inc.
02.02.26
02.02.27
19.06.26

